<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894699</url>
  </required_header>
  <id_info>
    <org_study_id>ARX-C-007</org_study_id>
    <nct_id>NCT00894699</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcelRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcelRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of a study medication
      that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This
      drug is being designed to provide mild sedation as well as reduce anxiety and pain before and
      during a procedure (in this case elective abdominal liposuction).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)</measure>
    <time_frame>4 hour study period</time_frame>
    <description>The primary efficacy endpoint of the study is the sedation level as assessed by the 10-point RASS, where unarousable is graded as minus 5 (- 5) and combative is graded as plus 4 (+ 4). The RASS was assessed at 15 time points throughout the four hour study period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sedation</condition>
  <condition>Anxiety</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose of sublingual Placebo NanoTab™</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)</intervention_name>
    <description>Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo NanoTab™</intervention_name>
    <description>Single dose of sublingual placebo NanoTab™</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must have provided written informed consent to participate in the study.

          2. Male or female patient between 18 to 60 (inclusive) years of age.

          3. Patient is planning to undergo an elective outpatient abdominal liposuction procedure.

          4. Patient must be classified as American Society of Anesthesiologists (ASA) class I -
             III.

          5. Patient must have Body Mass Index [BMI = weight (kg)/height (m2)] between 20 and 35,
             inclusively.

          6. Female patients of childbearing potential must be using an effective method of birth
             control at the time of the screening visit and for 30 days following the dosing of
             study medication. Acceptable methods of birth control include oral or transdermal
             contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant
             or injection, abstinence, vaginal ring, or sterilization of partner. The reason for
             non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy,
             hysterectomy, or postmenopausal for ≥1 year, must be specified. Patients using
             hormonal forms of contraception must also be willing to use a barrier method of
             contraception from screening through 30 days following the dose of study medication.

          7. Patient is willing to receive antibiotics as per the normal practice of the surgeon.

          8. Patient understands that preoperative analgesics or anxiolytics are not permitted.

          9. Patient is willing to avoid caffeine and alcohol use within 24 hours before the
             procedure.

         10. The patient must be willing and able to understand the study procedures and the use of
             pain and anxiety scales, and to communicate meaningfully with the study personnel.

         11. The patient must have a caregiver available to escort the patient home following the
             procedure.

        Exclusion Criteria:

          1. Patient who is expected to require less than 400 cc or more than 700 cc of abdominal
             fat removal during the procedure.

          2. Patient has previously not responded to opioid analgesics for treatment of pain.

          3. Patient has previously not responded to benzodiazepines for treatment of anxiety.

          4. Patient is currently taking any opioid or has taken any opioid for more than 7
             consecutive days of daily use within the past 3 months prior to the procedure.

          5. Patient is currently taking any benzodiazepine or has taken any benzodiazepine for
             more than 7 consecutive days within the past 3 months prior to the procedure.

          6. Patient is taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14
             days prior to enrolling in the study.

          7. Patient has an allergy or hypersensitivity to opioids.

          8. Patient who is currently taking anti-inflammatory drugs, including steroids.

          9. Use of drugs which are P450 3A4 inducers or inhibitors within 30 days of dosing
             including alprazolam, chlorpheniramine, cimetidine, fluoxetine, haloperidol,
             ketoconazole, itraconazole, erythromycin, clarithromycin, sildenafil, simvastatin, St.
             John's Wort.

         10. Patient who is taking calcium channel blockers or beta blockers.

         11. Patient who will consume grapefruit, or products made with grapefruit, within 3 days
             of study medication dosing.

         12. Patient with a history of chronic obstructive pulmonary disease (COPD) or any other
             respiratory condition or active pulmonary disease.

         13. Patient currently has sleep apnea that has been documented by a sleep laboratory
             study.

         14. Patient is a woman who is pregnant or lactating.

         15. Patient has a history of an anxiety disorder.

         16. Patients with oral mucositis or stomatitis.

         17. Patient has a history of drug, prescription medicine, or alcohol abuse within the past
             2 years.

         18. Patient used an investigational drug or device within 30 days of screening visit.

         19. Patient has undergone a liposuction procedure previously.

         20. Patient has a history of migraine or chronic headache.

         21. Patient who has a positive urine screen for drugs of abuse at screening or on the day
             of procedure.

         22. Patient who has a positive alcohol screen on the day of the procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Palmer, M.D., PhD</last_name>
    <role>Study Director</role>
    <affiliation>AcelRx Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research, Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2009</study_first_posted>
  <results_first_submitted>January 10, 2014</results_first_submitted>
  <results_first_submitted_qc>May 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2014</results_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>procedural sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Triazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated 22 June 2009 and completed 11 September 2009. One clinical research center participated in the study</recruitment_details>
      <pre_assignment_details>Patients were to be between 18 and 60 years of age, generally healthy, and who are expected to require more than 400 cc or less than 700 cc of abdominal fat removal during the procedure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™</title>
          <description>Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™</description>
        </group>
        <group group_id="P2">
          <title>Single Dose of Placebo NanoTab™</title>
          <description>Single dose of sublingual Placebo NanoTab™</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sufentanil/Triazolam NanoTab™</title>
          <description>Single dose of sublingual Sufentanil/Triazolam 15/200 mcg NanoTab™</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single dose of Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="9.8"/>
                    <measurement group_id="B2" value="37.3" spread="7.7"/>
                    <measurement group_id="B3" value="36.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)</title>
        <description>The primary efficacy endpoint of the study is the sedation level as assessed by the 10-point RASS, where unarousable is graded as minus 5 (- 5) and combative is graded as plus 4 (+ 4). The RASS was assessed at 15 time points throughout the four hour study period.</description>
        <time_frame>4 hour study period</time_frame>
        <population>ITT population were those patients that took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil 15 mcg/Triazolam NanoTab™ 200 mcg</title>
            <description>Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™</description>
          </group>
          <group group_id="O2">
            <title>Placebo NanoTab™</title>
            <description>Single dose of sublingual Placebo NanoTab™</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)</title>
          <description>The primary efficacy endpoint of the study is the sedation level as assessed by the 10-point RASS, where unarousable is graded as minus 5 (- 5) and combative is graded as plus 4 (+ 4). The RASS was assessed at 15 time points throughout the four hour study period.</description>
          <population>ITT population were those patients that took at least one dose of study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.44" spread=".82"/>
                    <measurement group_id="O2" value="0.79" spread=".86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 hours.</time_frame>
      <desc>A telephone call was placed to each patient 24 hours after dosing to inquire about the patients' overall health. If AEs were reported, they were documented in the clinical database.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sufentanil/Triazolam NanoTab™</title>
          <description>Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single dose of Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>All events listed in this table were considered possibly or probably related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Palmer, MD, PhD</name_or_title>
      <organization>AcelRx Pharmaceuticals, Inc.</organization>
      <phone>650-216-3504</phone>
      <email>ppalmer@acelrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

